MHRA approval for Byannli

1 February 2022

Byannli (paliperidone palmitate) has been approved in Great Britain for the maintenance treatment of schizophrenia in adults who are clinically stable on one-monthly or three-monthly paliperidone palmitate.

The long-acting atypical antipsychotic therapy from Johnson & Johnson's (NYSE: JNJ) Janssen subsidiary becomes the first twice-yearly treatment for adults living with schizophrenia to be approved by the Medicines and Healthcare products Agency (MHRA), with the longest available dosing interval for an antipsychotic medication in Great Britain.

"A key milestone in our ongoing work to help change the paradigm in treating schizophrenia with long-acting treatments"David Taylor, director of pharmacy and pathology at the Maudsley Hospital, said: “Schizophrenia is a chronic and severe brain disorder, and antipsychotic medication plays an important role in its treatment. However, many people with the illness experience relapses which are often caused by poor adherence to oral medication.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK